巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    NGM Biopharmaceuticals

    NGM
    16.870
    0.620
    3.82%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・NGM Biopharmaceuticals - 延遲價格・最後更新於 10/08 2:07
    最高位
    16.970
    最低位
    16.520
    開市價
    --
    前收市價
    16.250
    成交量(千)
    2.97
    成交額(百萬)
    0.48
    買入
    16.780
    賣出
    16.980
    每手股數
    --
    市值(百萬)
    1,355.77
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    27.250 - 10.490
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    NGM Biopharmaceuticals
    證券代碼
    NGM.US
    所屬板塊
    Biotechnology
    公司業務
    NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.
    發行量
    78049340
    公司總部
    333 Oyster Point Boulevard
    公司網址
    https://www.ngmbio.com
    公司電郵
    ir@ngmbio.com
    公司電話
    +1 650 243-5555
    暫無內容

    關於

    NGM Biopharmaceuticals(NGM.US)所屬的行業板塊為Biotechnology。
    NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.
    詳細公司背景可參考: https://www.ngmbio.com